What is Monopar Therapeutics Inc (MNPR) stock price today?

Monopar Therapeutics Inc (MNPR) currently trades at $52.15 per share. The stock has a market capitalization of $361.51M and a P/E ratio of —x.

Is MNPR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Monopar Therapeutics Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is —.

Is Monopar Therapeutics Inc financially healthy?

Monopar Therapeutics Inc's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of — places it in the —.

MNPR

Monopar Therapeutics Inc

NASDAQ: MNPR · HEALTHCARE · BIOTECHNOLOGY

$52.15

+4.05% today

Updated 2026-04-30

Market cap

$361.51M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.85

Dividend yield

—

52W range

$28 – $105

Volume

0.2M

Market cap

$361.51M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.85

Dividend yield

—

52W range

$28 – $105

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.8

Quality

B+

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$112.79

+116.28%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

4 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Thin margins at 0.00%

- Negative free cash flow $-3.37M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-10.49M	$-8.40M	$-15.59M	$-13.72M	$-5.20M
EPS	—	—	—	—	$-1.85
Free cash flow	$-7.23M	$-7.86M	$-6.40M	$-12.20B	$-3.37M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-31	ROBINSON, CHANDLER	Sale	6,732	—
2026-03-31	ROBINSON, CHANDLER	Buy	6,732	—
2026-03-31	ROBINSON, CHANDLER	Sale	1,972	$54.79

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MNPR	$361.51M	28	4.3	3.0	5.0	7.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Monopar Therapeutics Inc trades at $52.15. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score.

Frequently asked questions

What is Monopar Therapeutics Inc's stock price?

Monopar Therapeutics Inc (MNPR) trades at $52.15.

Is Monopar Therapeutics Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Monopar Therapeutics Inc (MNPR)?

The analyst target price is $112.79, representing +116.3% upside from the current price of $52.15.

Piotroski F-Score?

4/9 — moderate financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.monopartx.com

Quick metrics

P/S ratio—

ROE-14.20%

Beta1.66

50D MA$55.91

200D MA$62.56

Shares out0.01B

Float0.00B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MNPR vs LLY →MNPR vs JNJ →MNPR vs ABBV →Stock screener →